Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06629389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

Study acronym: CBD-EP-2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 5, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2024 to Nov 28, 2024
    • Site details revised
    v4
  2. Site contact updatedv3
  3. Secondary endpoints revised (10)v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.
Trial Details
NCT Number NCT06629389
Lead Sponsor Laboratorio Elea Phoenix S.A.
Conditions
(from sponsor)		 Parkinson Disease
Related terms Marijuana Abuse, Parkinson Disease
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov